Synovial Sarcoma, X Breakpoint 7 (SSX7) (Middle Region) Peptide
SSX7
Reactivité: Humain
Hôte: Synthetic
BP, WB
N° du produit ABIN984482
Aperçu rapide pour Synovial Sarcoma, X Breakpoint 7 (SSX7) (Middle Region) Peptide (ABIN984482)
Antigène
SSX7
(Synovial Sarcoma, X Breakpoint 7 (SSX7))
Origine
Humain
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB)
Protein Region
Middle Region
Attributs du produit
This is a synthetic peptide designed for use in combination with anti-SSX7 antibody (Catalog #: ARP51717_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
Each Investigator should determine their own optimal working dilution for specific applications.
Restrictions
For Research Use only
Format
Lyophilized
Reconstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Concentration
1 mg/mL
Buffer
Final peptide concentration is 1 mg/mL in PBS.
Conseil sur la manipulation
Avoid repeated freeze-thaw cycles.
Stock
-20 °C
Stockage commentaire
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Antigène
SSX7
(Synovial Sarcoma, X Breakpoint 7 (SSX7))
Sujet
SSX7 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X,18) translocation characteristically found in all synovial sarcomas. This gene appears not to be involved in this type of chromosome translocation.The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X,18) translocation characteristically found in all synovial sarcomas. This gene appears not to be involved in this type of chromosome translocation.